Key Highlights
- USPTO issues Notice of Allowance for 4-1BB and OX40 binding protein patent
- Patent covers bispecific antibodies engineered for oncology applications
- Shares rose 10% to $4.96 in extended trading
- Allowance strengthens intellectual property position in cancer immunotherapy
- Validates company's proprietary antibody platform
Aptevo Therapeutics Inc. announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office covering its 4-1BB and OX40 binding proteins, a development the company says strengthens its intellectual property position in an increasingly competitive field of next-generation cancer immunotherapy. The allowed patent encompasses bispecific antibodies and related compositions specifically engineered to engage both targets simultaneously, a design intended to amplify immune activation against tumors beyond what single-target approaches typically achieve.
Both 4-1BB and OX40 are costimulatory receptors found on immune cells, and each has attracted substantial pharmaceutical industry interest as a potential lever for enhancing anti-tumor immune responses when engaged appropriately. Bispecific antibodies that target both receptors concurrently aim to capture complementary biological effects — theoretically producing a more robust or durable immune activation than agents hitting either target alone — though the clinical translation of dual-costimulatory approaches has historically proven more difficult than preclinical rationale alone would suggest.
For Aptevo, a company with a multi-program bispecific antibody platform, securing allowed intellectual property around this specific mechanism provides a measure of competitive protection as larger, better-capitalized players continue to invest heavily in costimulatory bispecific approaches. Patent allowances of this kind do not guarantee commercial success, but they do establish a legal foundation that can support licensing discussions, partnership negotiations, or eventual product exclusivity should the underlying science advance into and through clinical development.
The market's reaction was notably positive, with shares up 10% to $4.96 in extended-hours trading, a reflection of how meaningfully intellectual property catalysts can move small-cap biotech valuations, even absent accompanying clinical data. For Aptevo, the allowance adds a tangible asset to a platform still working to translate its antibody engineering capabilities into late-stage clinical progress.
What does Aptevo's new patent allowance cover?
The USPTO Notice of Allowance covers bispecific antibodies and related compositions targeting both 4-1BB and OX40 binding proteins, engineered for oncology applications.
Why did Aptevo shares rise on the patent news?
Shares climbed 10% to $4.96 in extended trading as investors credited the allowance with strengthening the company's competitive position in cancer immunotherapy, even without new clinical data.
This article is for informational purposes and does not constitute investment advice.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...